- Patent Title: Compositions and methods for inhibiting expression of RRM2 genes
-
Application No.: US15415415Application Date: 2017-01-25
-
Publication No.: US09938531B2Publication Date: 2018-04-10
- Inventor: John Frederick Boylan , Birgit Bramlage , Markus Hossbach , John Reidhaar-Olson
- Applicant: Arrowhead Pharmaceuticals, Inc.
- Applicant Address: US CA Pasadena
- Assignee: Arrowhead Pharmaceuticals, Inc.
- Current Assignee: Arrowhead Pharmaceuticals, Inc.
- Current Assignee Address: US CA Pasadena
- Agent Robert Michael Teigen
- Priority: EP10187851 20101018
- Main IPC: C12N15/113
- IPC: C12N15/113

Abstract:
The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a RRM2 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of a RRM2 gene using said pharmaceutical composition; and methods for inhibiting the expression of RRM2 in a cell.
Public/Granted literature
- US20170137827A1 Compositions and Methods for Inhibiting Expression of RRM2 Genes Public/Granted day:2017-05-18
Information query
IPC分类: